Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery

被引:19
|
作者
Taylor, NA
Liao, ZX
Stevens, C
Walsh, G
Roth, J
Putnam, J
Fossella, F
Allen, P
Cox, JD
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 56卷 / 03期
关键词
non-small-cell lung cancer; postoperative radiotherapy; induction chemotherapy; surgery;
D O I
10.1016/S0360-3016(03)00063-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the effectiveness of postoperative radiotherapy (RT) in patients with Stage IIB and Stage IIIA non-small-cell lung cancer (NSCLC) treated with induction chemotherapy followed by surgery. Methods and Materials: We retrospectively reviewed the treatment records of 98 patients (58 men and 40 women; median age 61 years, range 31-91) with Stage IIB and Stage IIIA NSCLC who were treated with induction chemotherapy followed by surgery at our institution between January 1990 and December 2000. Patients were grouped by treatment (chemotherapy/surgery alone vs. chemotherapy/surgery/RT), by disease stage and nodal classification. The rates of local control (LC), disease-specific survival, disease-free survival, and overall survival (OS) were calculated using the Kaplan-Meier method. Results: Of the 98 patients, 40 had Stage IIB and 58 had Stage IIIA. The clinical disease stage and N stage were significantly greater in those patients who underwent RT than in those who did not; however, no statistically significant differences were identified in the additional characteristics between those receiving and not receiving RT within each stage or nodal group. The overall 5-year actuarial LC rate was 81% in the RT group and 54% in the chemotherapy/surgery-alone group (p = 0.07). Postoperative RT significantly improved the 5-year LC rate in patients with Stage IIIA disease (from 35% to 82%,p = 0.01). Postoperative RT did not significantly improve the 5-year OS rate (30% with RT vs. 49% without) for all patients or for patients with Stage IIIA disease. The disease-specific survival and disease-free survival rates did not differ between the treatment groups. Patients who responded to induction chemotherapy had a significantly greater 5-year OS rate (49%) than did those with stable or progressive disease (22%, p = 0.003). Conclusion: Postoperative RT in patients with Stage IIIA NSCLC treated with induction chemotherapy followed by surgery significantly improved LC without improving OS. Significantly improved survival was observed in all patients who responded to induction chemotherapy compared with those with stable or progressive disease. (C) 2003 Elsevier Inc.
引用
收藏
页码:616 / 625
页数:10
相关论文
共 50 条
  • [41] Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer
    Gopal, R
    Starkschall, G
    Tucker, SL
    Cox, JDC
    Liao, ZX
    Hanus, M
    Kelly, JF
    Stevens, CW
    Komaki, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 114 - 120
  • [42] Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer
    Sher, David J.
    Fidler, Mary Jo
    Liptay, Michael J.
    Koshy, Matthew
    LUNG CANCER, 2015, 88 (03) : 267 - 274
  • [43] Controversies in the management of stage IIIA non-small-cell lung cancer
    Santos, Edgardo S.
    Castrellon, Aurelio
    Blaya, Marcelo
    Raez, Luis E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1913 - 1929
  • [44] Multidisciplinary Treatment of Stage IIIA Non-Small-Cell Lung Cancer
    Yendamuri, Sai
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (07) : 607 - +
  • [45] Multimodality therapy in stage IIIA non-small-cell lung cancer
    Kim, SY
    Lee, YS
    Jung, SS
    Yun, WJ
    Kim, JO
    Cho, MJ
    Lim, SR
    Kim, JS
    Roh, YH
    LUNG CANCER, 2004, 45 : S57 - S58
  • [46] Is surgery indicated for stage IIIA-N2 non-small-cell lung cancer?
    Gounant, V.
    Lavole, A.
    Epaud, C.
    Rosencher, L.
    Milleron, B.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2007, 63 (03) : 135 - 137
  • [47] A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)
    Nagai, K
    Tsuchiya, R
    Mori, T
    Tada, H
    Ichinose, Y
    Koike, T
    Kato, H
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (02): : 254 - 260
  • [48] POSTOPERATIVE CHEMOTHERAPY FOR NON-SMALL-CELL LUNG-CANCER
    HOLMES, EC
    CHEST, 1993, 103 (01) : S30 - S34
  • [49] Stage IIIA Non-small-cell Lung Carcinoma Is surgical Resection useful after concurrent Chemotherapy and Radiotherapy?
    Busk, H.
    PNEUMOLOGE, 2010, 7 (03): : 200 - 201
  • [50] Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients:: A phase II trial
    Pallares, C.
    Capdevila, J.
    Paredes, A.
    Farre, N.
    Ciria, J. P.
    Membrive, I.
    Basterrechea, L.
    Gomez-Segura, G.
    Barnadas, A.
    LUNG CANCER, 2007, 58 (02) : 238 - 245